A summary of research published in The Lancet Respiratory Medicine.
Findings from the largest bronchiectasis study to date were published last month (24 April 2023). The findings will help us to understand the condition and how it affects people.
Results came from the EMBARC (European Multicentre Bronchiectasis Audit and Research Collaboration) network. ERS and ELF support this network, which encourages research into non-cystic fibrosis bronchiectasis.
What did the study look at?
16,963 people took part in the study. Information was collected on their health and treatment since 2015. This included hospital visits and the number of flare ups (exacerbations) they had.
What do the results show?
Key findings include:
Why is this important?
This is the largest published study of bronchiectasis to date. It helps us understand how the condition affects people and sheds light on the causes and treatments available. The authors believe that testing could help us understand more about the causes of bronchiectasis. Research into why some bacteria are less common in Northern Europe could find ways to prevent infections elsewhere. Future work should also focus on improving diagnosis and treatment in Central and Eastern Europe.
Read the original research paper:
Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)
For more information on bronchiectasis, visit our Patient Priorities site: https://europeanlunginfo.org/bronchiectasis or listen to our patient stories: https://europeanlung.org/en/people-and-partners/your-experiences/?conditions=bronchiectasis
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.